MX2023006291A - Metodos para purificar proteinas que contienen fc. - Google Patents
Metodos para purificar proteinas que contienen fc.Info
- Publication number
- MX2023006291A MX2023006291A MX2023006291A MX2023006291A MX2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- protein
- purifying
- resin
- elution buffer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Storage Device Security (AREA)
Abstract
La presente invención se refiere a métodos para purificar proteínas que contienen regiones Fc, tales como anticuerpos y proteínas de fusión de Fc. En particular, la presente invención se refiere a un método de purificación que da como resultado niveles reducidos de agregados de proteínas que comprende adsorber una proteína que contiene una región Fc en una resina de proteína A sensible a la temperatura y eluir la proteína desde la resina a una temperatura inferior a 35 °C con un tampón de elución que comprende un agente caotrópico, un alcohol de azúcar, y al menos un aminoácido. También se describen métodos para separar los anticuerpos ensamblados por completo de las formas de semianticuerpo de los mismos usando el tampón de elución.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365943P | 2016-07-22 | 2016-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006291A true MX2023006291A (es) | 2023-06-13 |
Family
ID=59656168
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000903A MX2019000903A (es) | 2016-07-22 | 2017-07-21 | Metodos para purificar proteinas que contienen fc. |
| MX2023006291A MX2023006291A (es) | 2016-07-22 | 2019-01-21 | Metodos para purificar proteinas que contienen fc. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000903A MX2019000903A (es) | 2016-07-22 | 2017-07-21 | Metodos para purificar proteinas que contienen fc. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11312745B2 (es) |
| EP (1) | EP3487867B1 (es) |
| JP (2) | JP7092744B2 (es) |
| KR (2) | KR102435801B1 (es) |
| CN (2) | CN115925780B (es) |
| AU (2) | AU2017298984B2 (es) |
| CA (2) | CA3031469C (es) |
| IL (2) | IL285146B (es) |
| MA (1) | MA45721A (es) |
| MX (2) | MX2019000903A (es) |
| SG (1) | SG11201900573UA (es) |
| WO (1) | WO2018018011A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202102713TA (en) * | 2018-09-21 | 2021-04-29 | Teneobio Inc | Methods for purifying heterodimeric, multispecific antibodies |
| MX2021003976A (es) | 2018-10-11 | 2021-05-27 | Amgen Inc | Procesamiento posterior de constructos de anticuerpos biespecificos. |
| SG11202106370WA (en) * | 2019-01-16 | 2021-07-29 | Regeneron Pharma | Method and system of identifying and quantifying antibody fragmentation |
| KR102286892B1 (ko) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | 안과용 단백질 제제의 정제방법 |
| CN110724204B (zh) * | 2019-11-18 | 2021-10-22 | 广东菲鹏制药股份有限公司 | Fc融合蛋白的纯化方法 |
| CN112881675A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏生物有限公司 | IgM抗体检测稀释液 |
| WO2021207657A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| WO2022061035A1 (en) * | 2020-09-16 | 2022-03-24 | Waters Technologies Corporation | Improved size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase |
| EP4421089A4 (en) * | 2021-10-19 | 2026-01-07 | Alteogen Inc | METHOD FOR PURIFYING A FUSION PROTEIN HAVING AN IGG FC DOMAIN |
| CN113980092B (zh) * | 2021-12-09 | 2024-05-14 | 上海药明生物技术有限公司 | 一种蛋白质亲和纯化方法 |
| CN116165290B (zh) * | 2021-12-17 | 2025-06-27 | 复旦大学 | 一种抗体药物研发流程中工程细胞株的筛选方法 |
| CN116271982B (zh) * | 2022-11-30 | 2024-01-09 | 杭州广科安德生物科技有限公司 | 一种血液高丰度蛋白免疫亲和柱的再生方法 |
| EP4634201A1 (en) * | 2022-12-12 | 2025-10-22 | H. Lundbeck A/S | Arginine wash in protein purification |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| WO1999053059A1 (en) * | 1998-04-16 | 1999-10-21 | Genentech, Inc. | Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1805320B1 (en) | 2004-10-22 | 2014-09-03 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| BRPI0611600B8 (pt) * | 2005-06-17 | 2021-05-25 | Wyeth Corp | método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit |
| WO2007081906A2 (en) * | 2006-01-06 | 2007-07-19 | Amgen Inc. | Purification by column-chromatography using eluants containing organic solvents |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| US10982250B2 (en) * | 2006-09-18 | 2021-04-20 | Genentech, Inc. | Methods of protein production |
| WO2008143199A1 (ja) * | 2007-05-21 | 2008-11-27 | Nomadic Bioscience Co., Ltd. | 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| JP5529869B2 (ja) * | 2008-08-14 | 2014-06-25 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法 |
| SG176963A1 (en) | 2009-06-22 | 2012-02-28 | Amgen Inc | Refolding proteins using a chemically controlled redox state |
| LT3660032T (lt) * | 2009-06-25 | 2026-02-25 | Amgen Inc. | Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai |
| CN102712696A (zh) * | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| CN102382190B (zh) * | 2010-09-01 | 2014-04-09 | 山东新时代药业有限公司 | 分离和去除TNFR-Fc融合蛋白中寡聚体的方法 |
| US20130317172A1 (en) | 2010-12-24 | 2013-11-28 | Nomadic Bioscience Co., Ltd. | Method for immobilizing temperature responsive protein a |
| JP6280499B2 (ja) | 2011-07-08 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆｃ融合タンパク質の精製方法 |
| JP6420756B2 (ja) * | 2012-03-28 | 2018-11-07 | ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ | アフィニティークロマトグラフィーマトリックス |
| EP2889617B1 (en) | 2012-08-27 | 2017-10-11 | Asahi Kasei Medical Co., Ltd. | Antibody purification method by means of temperature-responsive chromatography |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| AP2016009222A0 (en) * | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2017
- 2017-07-21 US US16/093,994 patent/US11312745B2/en active Active
- 2017-07-21 CA CA3031469A patent/CA3031469C/en active Active
- 2017-07-21 WO PCT/US2017/043384 patent/WO2018018011A2/en not_active Ceased
- 2017-07-21 KR KR1020197003162A patent/KR102435801B1/ko active Active
- 2017-07-21 MX MX2019000903A patent/MX2019000903A/es unknown
- 2017-07-21 AU AU2017298984A patent/AU2017298984B2/en active Active
- 2017-07-21 CA CA3218290A patent/CA3218290A1/en active Pending
- 2017-07-21 IL IL285146A patent/IL285146B/en unknown
- 2017-07-21 SG SG11201900573UA patent/SG11201900573UA/en unknown
- 2017-07-21 KR KR1020227028721A patent/KR102579850B1/ko active Active
- 2017-07-21 CN CN202210979746.6A patent/CN115925780B/zh active Active
- 2017-07-21 EP EP17754514.2A patent/EP3487867B1/en active Active
- 2017-07-21 JP JP2019503247A patent/JP7092744B2/ja active Active
- 2017-07-21 MA MA045721A patent/MA45721A/fr unknown
- 2017-07-21 CN CN201780045463.1A patent/CN109563125B/zh active Active
-
2019
- 2019-01-21 MX MX2023006291A patent/MX2023006291A/es unknown
- 2019-01-21 IL IL264375A patent/IL264375B/en unknown
-
2022
- 2022-06-15 JP JP2022096278A patent/JP7411020B2/ja active Active
-
2023
- 2023-08-31 AU AU2023222915A patent/AU2023222915B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190127418A1 (en) | 2019-05-02 |
| AU2023222915A1 (en) | 2023-09-21 |
| SG11201900573UA (en) | 2019-02-27 |
| KR20220120716A (ko) | 2022-08-30 |
| JP2019528255A (ja) | 2019-10-10 |
| EP3487867A2 (en) | 2019-05-29 |
| KR102579850B1 (ko) | 2023-09-18 |
| JP2022120138A (ja) | 2022-08-17 |
| EP3487867B1 (en) | 2026-04-01 |
| JP7411020B2 (ja) | 2024-01-10 |
| CN109563125A (zh) | 2019-04-02 |
| AU2017298984A1 (en) | 2019-02-07 |
| AU2023222915B2 (en) | 2026-01-22 |
| MX2019000903A (es) | 2019-05-15 |
| CN115925780A (zh) | 2023-04-07 |
| CA3031469C (en) | 2025-11-18 |
| MA45721A (fr) | 2019-05-29 |
| EP3487867C0 (en) | 2026-04-01 |
| CA3218290A1 (en) | 2018-01-25 |
| AU2017298984B2 (en) | 2023-08-31 |
| IL285146A (en) | 2021-08-31 |
| US11312745B2 (en) | 2022-04-26 |
| WO2018018011A2 (en) | 2018-01-25 |
| JP7092744B2 (ja) | 2022-06-28 |
| CN115925780B (zh) | 2025-11-04 |
| IL264375A (en) | 2019-02-28 |
| CA3031469A1 (en) | 2018-01-25 |
| IL285146B (en) | 2022-09-01 |
| IL264375B (en) | 2021-09-30 |
| KR20190037247A (ko) | 2019-04-05 |
| KR102435801B1 (ko) | 2022-08-25 |
| CN109563125B (zh) | 2022-08-09 |
| WO2018018011A3 (en) | 2018-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000903A (es) | Metodos para purificar proteinas que contienen fc. | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| WO2013177115A3 (en) | Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography | |
| BR112012017124B8 (pt) | método para produzir e para purificar um multímero polipeptídico | |
| BR112012020254A2 (pt) | método para a purificação de anticorpos a partir de uma mistura de proteína e, unidade operacional única. | |
| MX371442B (es) | VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB. | |
| MX372711B (es) | Metodos para la purificacion de arilsulfatasa a. | |
| ES2690542T3 (es) | Método para purificar variantes de fenilalanina amoníaco-liasa procariotas | |
| BRPI0611600B8 (pt) | método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit | |
| MX350610B (es) | Proceso para la purificacion de anticuerpos monoclonales. | |
| EA201492177A1 (ru) | Очистка идуронат-2-сульфатазы | |
| MX395730B (es) | Uso de lavados alcalinos durante la cromatografia para remover impurezas. | |
| AU2014370873A1 (en) | Method for purifying antibody having low isoelectric point | |
| EP4389143A3 (en) | Selective reduction of cysteine residues in il-17 antibodies | |
| RU2014111820A (ru) | Способы элиминации вируса | |
| EP4389757A3 (en) | Methods for purifying antibodies | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| AR117418A1 (es) | Métodos para la purificación de polipéptidos usando polisorbatos | |
| AR104358A1 (es) | Método para la purificación de proteínas | |
| EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
| BR112016010191A2 (pt) | matriz de eluição e usos desta | |
| EA201691834A1 (ru) | Новый способ очистки гонадотропина | |
| AR096765A1 (es) | Métodos de adsorción en lecho expandido para el aislamiento de proteínas básicas de la leche incluyendo a la lactoferrina | |
| EA201790241A1 (ru) | Эффективная селективность в отношении рекомбинантных белков | |
| AR119546A1 (es) | Métodos para purificar anticuerpos |